NO20052223D0 - Tiazolforbindelser for behandling av neurodegenerative forstyrrelser - Google Patents

Tiazolforbindelser for behandling av neurodegenerative forstyrrelser

Info

Publication number
NO20052223D0
NO20052223D0 NO20052223A NO20052223A NO20052223D0 NO 20052223 D0 NO20052223 D0 NO 20052223D0 NO 20052223 A NO20052223 A NO 20052223A NO 20052223 A NO20052223 A NO 20052223A NO 20052223 D0 NO20052223 D0 NO 20052223D0
Authority
NO
Norway
Prior art keywords
treatment
neurodegenerative disorders
thiazole compounds
thiazole
compounds
Prior art date
Application number
NO20052223A
Other languages
English (en)
Other versions
NO20052223L (no
Inventor
Yuhpyng Liang Chen
Michael Leon Corinan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20052223D0 publication Critical patent/NO20052223D0/no
Publication of NO20052223L publication Critical patent/NO20052223L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54Nitrogen and either oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20052223A 2002-10-09 2005-05-06 Tiazolforbindelser for behandling av neurodegenerative forstyrrelser NO20052223L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41740002P 2002-10-09 2002-10-09
US46320903A 2003-06-17 2003-06-17
PCT/IB2003/004330 WO2004033439A1 (en) 2002-10-09 2003-09-29 Thiazole compounds for the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
NO20052223D0 true NO20052223D0 (no) 2005-05-06
NO20052223L NO20052223L (no) 2005-07-04

Family

ID=35306299

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052223A NO20052223L (no) 2002-10-09 2005-05-06 Tiazolforbindelser for behandling av neurodegenerative forstyrrelser

Country Status (28)

Country Link
US (1) US20040152747A1 (no)
EP (1) EP1551815A1 (no)
JP (1) JP2006504796A (no)
KR (1) KR20050070046A (no)
CN (1) CN1688557A (no)
AP (1) AP2005003274A0 (no)
AR (1) AR043051A1 (no)
AU (1) AU2003265068A1 (no)
BR (1) BR0314611A (no)
CA (1) CA2501803A1 (no)
CO (1) CO5550435A2 (no)
CR (1) CR7785A (no)
EC (1) ECSP055719A (no)
GT (1) GT200300219A (no)
IS (1) IS7738A (no)
MA (1) MA27451A1 (no)
MX (1) MXPA05002420A (no)
NL (1) NL1024499C2 (no)
NO (1) NO20052223L (no)
OA (1) OA12937A (no)
PA (1) PA8585001A1 (no)
PE (1) PE20040640A1 (no)
PL (1) PL376171A1 (no)
TN (1) TNSN05104A1 (no)
TW (1) TW200420550A (no)
UY (1) UY28011A1 (no)
WO (1) WO2004033439A1 (no)
ZA (1) ZA200502841B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
CA2524511A1 (en) 2003-05-12 2004-11-18 Pfizer Products Inc. Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
MXPA06001480A (es) * 2003-08-06 2006-05-15 Pfizer Prod Inc Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos.
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
RU2401262C2 (ru) * 2004-01-16 2010-10-10 Санофи-Авентис Производные алкиламинотиазола, их получение и их применение в терапии
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
DK1709018T3 (da) 2004-01-16 2011-11-14 Sanofi Sa Acylaminothiazolderivater og anvendelse deraf som beta-amyloid-hæmmere
CN1934091B (zh) * 2004-03-23 2012-02-08 辉瑞产品公司 治疗神经变性障碍的咪唑化合物
US7384968B2 (en) * 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
ES2401138T3 (es) 2004-08-13 2013-04-17 Genentech, Inc. Inhibidores basados en tiazol de enzimas que usan ATP
BRPI0611029A2 (pt) 2005-05-24 2010-08-10 Serono Lab derivados de tiazol e uso dos mesmos
FR2887879B1 (fr) * 2005-07-01 2008-09-26 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
JP2009508934A (ja) * 2005-09-22 2009-03-05 ファイザー・プロダクツ・インク 神経障害治療のためのイミダゾール化合物
CA2631750A1 (en) 2005-12-01 2007-06-07 The Scripps Research Institute Compositions and methods for inducing neuronal differentiation
KR20080091369A (ko) * 2006-01-18 2008-10-10 암젠 인크 단백질 키나제 b (pkb) 억제제로서 티아졸 화합물
EP1918286B1 (en) * 2006-11-05 2011-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thiazolhydrazides for treatment of neurodegenerative diseases
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
CA2693473A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
EP2349484A2 (en) * 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
US8889670B2 (en) 2009-02-18 2014-11-18 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the CB2 receptor
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2595959B1 (en) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
CN102351854B (zh) * 2011-07-29 2014-06-04 华中科技大学 氨基噻唑衍生物及制备方法和医药用途
WO2014159234A1 (en) * 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
WO2018235966A1 (ja) * 2017-06-21 2018-12-27 第一三共株式会社 Ep300/crebbp阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102890A1 (en) * 1991-05-28 1992-11-29 Soumya P. Sahoo Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
WO1999057098A2 (en) * 1998-05-01 1999-11-11 Abbott Laboratories Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
OA12937A (en) 2006-10-13
CN1688557A (zh) 2005-10-26
TNSN05104A1 (fr) 2007-05-14
KR20050070046A (ko) 2005-07-05
ZA200502841B (en) 2006-03-29
AR043051A1 (es) 2005-07-13
MA27451A1 (fr) 2005-07-01
ECSP055719A (es) 2005-07-06
JP2006504796A (ja) 2006-02-09
IS7738A (is) 2005-03-10
BR0314611A (pt) 2005-07-26
WO2004033439A1 (en) 2004-04-22
EP1551815A1 (en) 2005-07-13
PE20040640A1 (es) 2004-09-15
US20040152747A1 (en) 2004-08-05
TW200420550A (en) 2004-10-16
GT200300219A (es) 2004-05-18
MXPA05002420A (es) 2005-10-05
CO5550435A2 (es) 2005-08-31
PA8585001A1 (es) 2004-12-16
CR7785A (es) 2005-07-08
AP2005003274A0 (en) 2005-06-30
NL1024499C2 (nl) 2004-10-13
PL376171A1 (en) 2005-12-27
CA2501803A1 (en) 2004-04-22
NL1024499A1 (nl) 2004-04-13
UY28011A1 (es) 2004-04-30
NO20052223L (no) 2005-07-04
AU2003265068A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
NO20052223D0 (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
IS7941A (is) Bensasepínafleiður til að meðhöndla taugasjúkdóma
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
SE0502484L (sv) Behandling av neurodegenerativa tillstånd
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
EP1654260A4 (en) 6-LOW HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
GB0329874D0 (en) Compounds useful for the treatment of diseases
IL177955A0 (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
NO20045554L (no) Fremgangsmate for behandling av diabetes
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
EP1734957A4 (en) THIAZOLE SULFAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
NO20033804L (no) Karbamatforbindelser for behandling av smerte
EP1653952A4 (en) OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
NO20040497L (no) Amidinderivater for behandling av amyloidose
NO20030717L (no) Forbindelser for behandling av avhengighetsforstyrrelser
HK1080369A1 (zh) 用於治療多發性骨髓瘤的埃博霉素衍生物
IS8477A (is) Beta-laktöm til að meðhöndla MTK sjúkdóma
NO20033160D0 (no) Anordning for behandling av gravann